NCT04271202View on ClinicalTrials.gov

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Migraine
Interventions
DRUG

Emgality 120 MG in 1 ML Prefilled Syringe

Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.

Trial Locations (1)

02445

Pain Clinic at Beth Israel Deaconess Medical Center, Brookline

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER